Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index
The EMAs safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which the optic nerve is damaged by a sudden loss of blood supply
Administered by a nurse at your location
When the benefit outweighs the side effect, and when it might not For most patients, the metabolic benefits of GLP-1 therapy, including improved cardiovascular risk factors, better insulin sensitivity, reduced visceral fat, and meaningful weight loss, far outweigh a temporary or modest change in libido
doi: 10.1507/endocrj.47.supplmarch_s53 25 HosodaH.KojimaM.MatsuoH.KangawaK
The weight loss is dramatic, up to 22.5 percent over 72 weeks
